• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec8
Oppenheimer Raises Capricor Therapeutics' Target Price to $54
16:57
Dec4
Roth MKM analyst maintains buy rating on Capricor Therapeutics
13:27
Dec3
Nippon Shinyaku's CAP-1002 shows positive results in third stage clinical trials for Duchenne Muscular Dystrophy
23:47
Capricor Therapeutics Announces Positive Results for Deramiocel in DMD Phase 3 Trial
12:22
Nov11
Capricor Therap released FY2025 Q3 earnings on November 10 After-Market (EST), actual revenue USD 0 (forecast USD 480K), actual EPS USD -0.5374 (forecast USD -0.5475)
00:00
Capricor Therap released FY2025 9 Months Earnings on November 10 After-Market EST, actual revenue USD 0, actual EPS USD -1.6387
00:00

Schedules & Filings

Schedules
Filings
Nov10
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -24.57 M, EPS -0.5374

Aug11
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -25.91 M, EPS -0.5668

May13
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -24.39 M, EPS -0.5344

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
BBGI
16.690
+312.10%
+12.640
SRV.RT
0.0900
+111.76%
+0.048
BEAT
1.550
+92.43%
+0.745
ENVB
10.330
+74.49%
+4.410
BDRX
6.720
+65.11%
+2.650
ASPC
16.810
+60.40%
+6.330
IRBT
5.240
+48.44%
+1.710
CGTL
0.9727
+47.40%
+0.313
MIGI
6.700
+45.65%
+2.100
PLAB
37.350
+45.39%
+11.660
View More